New pharmaceutically acceptable
salts of
trazodone (
trazodone hydrogen bromide and
trazodone 1-hydroxy-2-naphthonic
acid) for the treatment of
central nervous system disorders are synthesized and described. Although
trazodone salts are poorly crystalline, single-crystal X-ray diffraction data for
trazodone 1-hydroxy-2-naphthonic
acid were collected and analyzed as well as compared to the previously described crystal structure of commercially available
trazodone hydrochloride. The
powder samples of all new
salts were characterized by Fourier transform infrared spectroscopy, X-ray diffraction and 13C solid-state nuclear magnetic resonance spectroscopy. Spectroscopic studies were supported by gauge including projector augmented wave (GIPAW) calculations of
carbon chemical shielding constants. The main goal of our research was to find
salts with better physicochemical properties and to make an attempt to associate them with both the
anion structure and the most prominent interactions exhibited by the protonated
trazodone cation. The dissolution profiles of
trazodone from
tablets prepared from various
salts with
lactose monohydrate were investigated. The studies revealed that
salts with simple
anions show a fast release of the
drug while the presence of more complex
anion, more strongly interacting with the
cation, effects a slow-release profile of the active substance and can be used for the preparation of the tables with a delay or prolonged mode of action.